| [1] |
VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263 |
| [2] |
ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1 |
| [3] |
MCGLYNN KA, PETRICK JL, LONDON WT. Global epidemiology of hepatocellular carcinoma: An emphasis on demographic and regional variability[J]. Clin Liver Dis, 2015, 19(2): 223-238. DOI: 10.1016/j.cld.2015.01.001 |
| [4] |
Organ Transplantation Branch, Chinese Medical Doctor Association; Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.008 |
| [5] |
RIZVI S, WANG J, EL-KHOUEIRY AB. Liver cancer immunity[J]. Hepatology, 2020. [Epub ahead of print]
|
| [6] |
PARDEE AD, BUTTERFIELD LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities[J]. Oncoimmunology, 2012, 1(1): 48-55. DOI: 10.4161/onci.1.1.18344 |
| [7] |
PRIETO J, MELERO I, SANGRO B. Immunological landscape and immunotherapy of hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12): 681-700. DOI: 10.1038/nrgastro.2015.173 |
| [8] |
THOMSON AW, KNOLLE PA. Antigen-presenting cell function in the tolerogenic liver environment[J]. Nat Rev Immunol, 2010, 10(11): 753-766. DOI: 10.1038/nri2858 |
| [9] |
ZHONG M, ZHONG C, CUI W, et al. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-Ⅰ-deficient stemness-high human liver cancer cells[J]. BMC Cancer, 2019, 19(1): 439. DOI: 10.1186/s12885-019-5670-9 |
| [10] |
CHENG JW, SHI YH, FAN J, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2011, 137(10): 1445-1453. DOI: 10.1007/s00432-011-1014-0 |
| [11] |
RODRIGO E, LÓPEZ-HOYOS M, CORRAL M, et al. ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta-analysis[J]. Liver Transpl, 2012, 18(10): 1245-1253.
|
| [12] |
LIU F, XU L, SHENG C, et al. Optimization and application of an HPLC method for quantification of inosine-5'-monophosphate dehydrogenase activity as a pharmacodynamic biomarker of mycophenolic acid in Chinese renal transplant patients[J]. Clin Chim Acta, 2018, 485: 333-339. DOI: 10.1016/j.cca.2018.06.042 |
| [13] |
CHAE MS, KIM JW, CHUNG HS, et al. The impact of serum cytokines in the development of early allograft dysfunction in living donor liver transplantation[J]. Medicine (Baltimore), 2018, 97(16): e0400. DOI: 10.1097/MD.0000000000010400 |
| [14] |
RODRÍGUEZ-PERÁLVAREZ M, TSOCHATZIS E, NAVEAS MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199. DOI: 10.1016/j.jhep.2013.07.012 |
| [15] |
LERUT J, IESARI S, FOGUENNE M, et al. Hepatocellular cancer and recurrence after liver transplantation: What about the impact of immunosuppression?[J]. Transl Gastroenterol Hepatol, 2017, 2: 80. DOI: 10.21037/tgh.2017.09.06 |
| [16] |
ZHOU J, FAN J, WANG Z, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience[J]. World J Gastroenterol, 2006, 12(19): 3114-3118. DOI: 10.3748/wjg.v12.i19.3114 |
| [17] |
YANIK EL, CHINNAKOTLA S, GUSTAFSON SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634. DOI: 10.1002/lt.24395 |
| [18] |
THORAT A, JENG LB, YANG HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: Re-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg, 2017, 21(4): 205-211. DOI: 10.14701/ahbps.2017.21.4.205 |
| [19] |
JENG LB, LEE SG, SOIN AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study[J]. Am J Transplant, 2018, 18(6): 1435-1446. DOI: 10.1111/ajt.14623 |
| [20] |
GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10): 1260-1273. DOI: 10.1111/apt.15253 |
| [21] |
CHEN K, SHENG J, MA B, et al. Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients[J]. Transplantation, 2019, 103(5): 929-937. DOI: 10.1097/TP.0000000000002647 |
| [22] |
CHEN ZS, HE F, ZENG FJ, et al. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma[J]. World J Gastroenterol, 2007, 13(39): 5273-5276. DOI: 10.3748/wjg.v13.i39.5273 |
| [23] |
Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese standard for diagnosis and treatment of immunosuppressive therapy and rejection in liver transplantation (2019 Edition)[J/CD]. Chin J Transplant(Electronic Edition), 2019, 13(4): 262-268. (in Chinese)
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 262-268.
|
| [24] |
GVNDISCH S, BOECKELER E, BEHRENDS U, et al. Glucocorticoids augment survival and proliferation of tumor cells[J]. Anticancer Res, 2012, 32(10): 4251-4261.
|
| [25] |
WEI Q, XU X, WANG C, et al. Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma[J]. Gut Liver, 2016, 10(4): 604-610. DOI: 10.5009/gnl15017 |
| [26] |
WEI Q, GAO F, ZHUANG R, et al. A national report from China Liver Transplant Registry: Steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437. DOI: 10.21147/j.issn.1000-9604.2017.05.07 |
| [27] |
DOHERTY DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review[J]. J Autoimmun, 2016, 66: 60-75.
|
| [28] |
SHI M, LIU Z, WANG Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection[J]. Stem Cells Transl Med, 2017, 6(12): 2053-2061. DOI: 10.1002/sctm.17-0134 |
| [29] |
LI S, ZHENG X, LI H, et al. Mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injury via inhibition of neutrophil recruitment[J]. J Immunol Res, 2018, 2018: 7283703.
|
DownLoad: